Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus - PubMed (original) (raw)
Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus
Sandeep Dhindsa et al. Endocr Pract. 2008 Nov.
Erratum in
- Endocr Pract. 2009 Jul-Aug;15(4):392
Abstract
Objective: To determine whether prostate-specific antigen (PSA) concentrations in type 2 diabetic men with hypogonadotrophic hypogonadism are lower than those in eugonadal men with type 2 diabetes and whether PSA concentrations are related to plasma testosterone concentrations.
Methods: In this cross-sectional study, we measured serum total testosterone, sex hormone-binding globulin, free testosterone, PSA, hematocrit, and hemoglobin A1c in consecutive type 2 diabetic men who presented to 2 endocrinology referral centers between January 2006 and January 2007. We collected other clinical and demographic data including age, height, weight, and ethnicity.
Results: Of 400 eligible patients, 280 men met inclusion criteria. Plasma PSA concentrations were lower in type 2 diabetic men with low free testosterone concentrations than in those with normal free testosterone concentrations (0.89 +/- 0.07 ng/mL vs 1.10 +/- 0.08 ng/mL, [corrected] P = .011). PSA concentrations were positively related to age (r = 0.34, P<.001), total testosterone (r = 0.29, P<.001), free testosterone (r = 0.17, P = .02), and sex hormone-binding globulin (r = 0.22, P<.001) and negatively related to body mass index (r = -0.28, P<.001). In stepwise backward regression analysis, PSA concentration was predicted by age (P<.001) and free testosterone (P<.001), but not by body mass index or sex hormone-binding globulin.
Conclusions: Plasma PSA concentrations are lower in type 2 diabetic men with hypogonadism than in eugonadal men with type 2 diabetes, and plasma PSA is related to age, plasma total testosterone concentrations, and free testosterone concentrations in patients with type 2 diabetes.
Similar articles
- Serum level of prostate-specific antigen in diabetic patients in Basrah, Iraq.
Al-Asadi JN, Al-Naama LM, Abdul-Kareem MM, Mashkoor FC. Al-Asadi JN, et al. Niger Postgrad Med J. 2017 Oct-Dec;24(4):240-244. doi: 10.4103/npmj.npmj_174_17. Niger Postgrad Med J. 2017. PMID: 29355164 - Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes.
Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. Bhatia V, et al. Diabetes Care. 2006 Oct;29(10):2289-94. doi: 10.2337/dc06-0637. Diabetes Care. 2006. PMID: 17003308 - Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
Haider A, Saad F, Doros G, Gooren L. Haider A, et al. Obes Res Clin Pract. 2014 Jul-Aug;8(4):e339-49. doi: 10.1016/j.orcp.2013.10.005. Epub 2013 Nov 5. Obes Res Clin Pract. 2014. PMID: 25091355 - Association between serum bioavailable testosterone concentration and the ratio of glycated albumin to glycated hemoglobin in men with type 2 diabetes.
Fukui M, Tanaka M, Hasegawa G, Yoshikawa T, Nakamura N. Fukui M, et al. Diabetes Care. 2008 Mar;31(3):397-401. doi: 10.2337/dc07-1898. Epub 2007 Nov 26. Diabetes Care. 2008. PMID: 18039803 - Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI. Grober ED, et al. Int J Impot Res. 2008 Nov-Dec;20(6):561-5. doi: 10.1038/ijir.2008.40. Epub 2008 Oct 9. Int J Impot Res. 2008. PMID: 18843272
Cited by
- Hypogonadotropic Hypogonadism in Men With Diabesity.
Dhindsa S, Ghanim H, Batra M, Dandona P. Dhindsa S, et al. Diabetes Care. 2018 Jul;41(7):1516-1525. doi: 10.2337/dc17-2510. Diabetes Care. 2018. PMID: 29934480 Free PMC article. Review. - Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.
Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Green K, Makdissi A, Chaudhuri A, Dandona P. Dhindsa S, et al. Clin Endocrinol (Oxf). 2016 Nov;85(5):772-780. doi: 10.1111/cen.13130. Epub 2016 Jul 18. Clin Endocrinol (Oxf). 2016. PMID: 27292585 Free PMC article. Clinical Trial. - Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.
Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H; Diabetes and Cancer Research Consortium. Renehan AG, et al. Diabetologia. 2012 Jun;55(6):1619-32. doi: 10.1007/s00125-012-2526-0. Epub 2012 Apr 4. Diabetologia. 2012. PMID: 22476948 Review. - Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity.
Dandona P, Dhindsa S. Dandona P, et al. J Clin Endocrinol Metab. 2011 Sep;96(9):2643-51. doi: 10.1210/jc.2010-2724. J Clin Endocrinol Metab. 2011. PMID: 21896895 Free PMC article. Review. - A practical guide to male hypogonadism in the primary care setting.
Dandona P, Rosenberg MT. Dandona P, et al. Int J Clin Pract. 2010 May;64(6):682-96. doi: 10.1111/j.1742-1241.2010.02355.x. Int J Clin Pract. 2010. PMID: 20518947 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous